The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
The transcriptional regulator c-JUN is a key mediator of the metastatic potential and drug resistance in melanoma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, c-JUN induces an EMT-like phenotype switch that may be responsible for the adaptive resistance to BRAF-MEK-ERK pathway inhibition in BRAFV600E melanoma cells [56].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [56]
Citations
Cites
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890 · cited 1×
“Functional category enrichment analysis using the NCBI Database for Annotation, Visualization and IntegratedDiscovery (DAVID) functional annotation toolwas used to identify GO terms (58) for the significant differentially expressed gene set.”
MethodSmyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196 · cited 2×
“These morphological and expression pattern alterations were consistent with previous descriptions of EMT programs in epithelial cancers (28) and of the phenotypic switch in melanoma (33).”
BackgroundResultImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationInhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationImproved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Self-citationEMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Self-citationCombined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,068
Self-citation
Cited by
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
Shaffer, S. M., Dunagin, M. C., Torborg, S. R., Torre, E. A., Emert, B., Krepler, C., Beqiri, M., Sproesser, K., Brafford, P. A., Xiao, M., et al. (2017) · Nature · doi:10.1038/nature22794 · Cited by 1,218
Phenotype plasticity as enabler of melanoma progression and therapy resistance
Arozarena, I., & Wellbrock, C. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0154-4 · Cited by 381
The JNK Signaling Pathway in Inflammatory Skin Disorders and Cancer
Hammouda, M., Ford, A., Liu, Y., & Zhang, J. (2020) · Cells · doi:10.3390/cells9040857 · Cited by 284
“The JNK signaling pathway mediates a wide range of cellular processes, including cell proliferation, survival, and migration [4,18,19], as well as cell apoptosis, senescence, and stress responses [20,21] (Figure 2).”
BackgroundThe CRUK IMAXT Grand Challenge Team, O’Flanagan, C. H., Campbell, K. R., Zhang, A. W., Kabeer, F., Lim, J. L. P., Biele, J., Eirew, P., Lai, D., McPherson, A., et al. (2019) · Genome Biology · doi:10.1186/s13059-019-1830-0 · Cited by 269
Fallahi‐Sichani, M., Becker, V., Izar, B., Baker, G. J., Lin, J., Boswell, S. A., Shah, P., Rotem, A., Garraway, L. A., & Sorger, P. K. (2017) · Molecular Systems Biology · doi:10.15252/msb.20166796 · Cited by 235
“Exposure of BRAF-mutant melanoma cells to MAPK inhibitors initially induces up-regulation of JNK/c-Jun signaling, a known regulator of EMT-related genes and of cell adhesion and ECM molecules (Liu et al, 2015; Ramsdale et al, 2015).”
Metadata
- Authors
- Ramsdale, R., Jorissen, R. N., Li, F. Z., Al-Obaidi, S., Ward, T., Sheppard, K. E., Bukczynska, P. E., Young, R. J., Boyle, S. E., Shackleton, M., Bollag, G., Long, G. V., Tulchinsky, E., Rizos, H., Pearson, R. B., McArthur, G. A., Dhillon, A. S., & Ferrao, P. T.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- The University of Melbourne (AU)
- Plexxikon (United States) (US)
- The University of Sydney (AU)
- University of Leicester (GB)
- Melanoma Institute Australia (AU)
- Corresponding author
- Ramsdale, Rachel
- Jorissen, Robert N.
- Ferrao, Petranel T.
- ORCID
- Venue
- Science Signaling
- Published
- 2015-08-18
- Volume
- 8
- Issue
- 390
- Pages
- ra82-ra82
- ISSN
- 1937-9145 (ISSN-L)
- 1945-0877
- OpenAlex
- W2318400076
- Cited by
- 143
- References
- 63
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 8 · 2023: 10 · 2022: 11 · 2021: 14 · 2020: 18 · 2019: 22 · 2018: 15 · 2017: 18 · 2016: 14
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Locations
- Science Signaling (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Peter MacCallum Cancer Foundation
- CASS Foundation
- National Health and Medical Research Council of Australia (1042980)
- China Scholarships Council
- Cancer Therapeutics CRC
- Australian National Health and Medical Research Council
- Pfizer Australia
- Victorian Endowment for Science, Knowledge and Innovation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- c-Jun, BRAF inhibitor resistance, BRAF V600-mutant melanoma, epithelial-mesenchymal transition, mesenchymal phenotype, Sprouty4, LEF1, JNK, transcriptional cofactors, drug resistance, BRAF/MEK inhibitors, cell migration, cell death
- MeSH terms
- Animals, Humans, Melanoma, Membrane Proteins, Microscopy, Fluorescence, Nerve Tissue Proteins, Phenotype, Blotting, Western, Gene Expression Regulation, Neoplastic, Mice, SCID, Mice, Inbred NOD, Mice, Knockout, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, MAP Kinase Signaling System, Xenograft Model Antitumor Assays, RNA Interference, Cell Line, Tumor, Tumor Burden, Protein Kinase Inhibitors, Intracellular Signaling Peptides and Proteins, JNK Mitogen-Activated Protein Kinases, Proto-Oncogene Proteins B-raf, Interleukin Receptor Common gamma Subunit, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.